Industry News
All SVB Leerink News
Top stories summarized by our editors
Top stories summarized by our editors

Tenants take 279K SF at Paramount Group office

9/7/2021

Paramount Group has signed deals for tenants to lease 279,000 square feet of space at 1301 Avenue of the Americas, a 1.7 million-square-foot Midtown Manhattan office. Credit Agricole CIB has signed a 167,000-square-foot lease and SVB Leerink has renewed and expanded its lease at 112,000 square feet.

Industry investment bank drawn to Tenn. for new site

8/26/2021

Boston-based investment bank SVB Leerink has opened an office in Nashville, Tenn., the company's second location in the Southeast. The company specializes in life sciences and health care, and officials said the additional site will enable continued growth of its health care services and health technology investment banking services.

preCARDIA bought by Abiomed

6/3/2021

preCARDIA, which is currently developing a minimally invasive, catheter-based system to treat acute decompensated heart failure, has been acquired by Abiomed. SVB Leerink analysts say the acquisition should "allow the company to build out their long-term product portfolio, potentially positioning the company well to, at some point, return to accelerating double-digit revenue growth."

Pharma stocks may be volatile during drug pricing debates

4/7/2021

Legislation that may be on the way to manage drug price inflation would have a negative effect on drugmaker stock prices in the short term, analysts at Cowen and SVB Leerink say. However, once legislation is passed or rejected, markets will stabilize and pharma stocks may rise, says Cowen analyst Steve Scala.

Senate will set direction of drug price policy

11/6/2020

Regardless of who wins the US presidency, it will be the Senate that determines what action, if any, the federal government takes to rein in rising drug prices, says SVB Leerink analyst Geoffrey Porges.

Castle Biosciences coverage initiated by Canaccord, SVB

8/20/2019

Canaccord Genuity and SVB Leerink initiated coverage of Castle Biosciences, which develops diagnostic tests for skin cancer. The firm has a price target of $26 and $28 per share for Canaccord and SVB, respectively.

Woodcock: FDA adapting to new clinical trial models, patient goals

7/12/2019

FDA Center for Drug Evaluation and Research Director Janet Woodcock expects the agency's new-drug approval rate to hold steady or increase, and says human genome sequencing will bolster the industry, according to SVB Leerink. Woodcock says the FDA is embracing new methods to generate data, such as basket trials and adaptive design, and is incorporating patient goals and preferences into review and approval decisions.

Analyst: Amazon poses little worry for PMBs owned by insurers

7/1/2019

Pharmacy benefit managers owned by insurance companies should not be worried about Amazon's entrance into the pharmaceutical industry, according to a report from SVB Leerink. Amazon's PillPack will have difficulty competing but poses some risk to large mail-order pharmacies, writes SVB Leerink's Ana Gupte.

Analyst: Amazon poses little worry for PMBs owned by insurers

6/24/2019

Pharmacy benefit managers owned by insurance companies should not be worried about Amazon's entrance into the pharmaceutical industry, according to a report from SVB Leerink. Amazon's PillPack will have difficulty competing but poses some risk to large mail-order pharmacies, writes SVB Leerink's Ana Gupte.